IBA's CFO Transition: A New Chapter for the Particle Accelerator Leader

IBA (Ion Beam Applications S.A.), the world leader in particle accelerator technology and the leading provider of proton therapy solutions for cancer treatment, has announced a significant change in its executive leadership. Soumya Chandramouli, the company's Chief Financial Officer (CFO) since 2016, will be stepping down from her role effective January 31, 2025. Henri de Romrée, the current Deputy CEO, will oversee the financial direction at the Group level until a new CFO is appointed. Thomas Pevenage, the Finance Director, will continue to lead the Group's Investor Relations function until further notice.

Soumya Chandramouli's departure marks the end of a 21-year tenure with IBA, during which she played a crucial role in the company's continued success. Working closely with Olivier Legrain, Henri de Romrée, and the Board and senior leadership team, Soumya's input helped shape the strategic direction of IBA. Her contributions throughout the years have propelled the progress of the business, underpinned by the financial structure she put in place. Olivier Legrain, CEO of IBA, praised Soumya's intelligence, professionalism, and outstanding work quality, stating that her contributions have left a lasting impact on the company's teams.

Henri de Romrée, who joined IBA as Chief Strategy Officer in November 2023 and was appointed Deputy CEO in March 2024, will ensure a smooth transition for the business until a successor is found. His extensive experience will be invaluable in maintaining the company's financial momentum during this period. Olivier Legrain expressed confidence in Henri's ability to manage the financial direction at the Group level, stating that his experience will ensure an efficient transition.

The transition of IBA's CFO role presents both opportunities and challenges for the company. While the departure of a long-serving executive like Soumya Chandramouli may lead to some adjustments in the company's strategic direction, IBA's focus on growth, financial stability, and innovation is expected to remain a priority. The opportunities and challenges that arise will depend on how effectively the new leadership can navigate the transition, integrate new ideas, and adapt to changing market conditions.

In conclusion, IBA's announcement of the CFO transition signals a new chapter for the company, with Henri de Romrée stepping in to ensure a smooth transition until a permanent successor is found. The company's strong financial track record, robust financial structure, and experienced leadership team will help ensure a successful transition and continued success in the proton therapy and particle accelerator technology sectors.